LONN.CH

517.2

-1.6%↓

LONN.CH

517.2

-1.6%↓

LONN.CH

517.2

-1.6%↓

LONN.CH

517.2

-1.6%↓

LONN.CH

517.2

-1.6%↓

Search

Roche Holding AG

Закрыт

СекторЗдравоохранение

365 -0.22

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

359.2

Макс.

365.8

Ключевые показатели

By Trading Economics

Доход

1.8B

5.5B

Продажи

15B

31B

P/E

Средняя по отрасли

22.53

84.243

Рентабельность продаж

17.892

Сотрудники

103,249

EBITDA

1.5B

8B

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-1.2B

288B

Предыдущая цена открытия

365.22

Предыдущая цена закрытия

365

Roche Holding AG График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

29 янв. 2026 г., 10:07 UTC

Отчет

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29 янв. 2026 г., 07:07 UTC

Отчет

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

18 нояб. 2025 г., 11:04 UTC

Главные движущие силы рынка

Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial

23 окт. 2025 г., 09:32 UTC

Отчет

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23 окт. 2025 г., 05:54 UTC

Отчет

Roche Raises Full-Year Earnings Outlook

29 янв. 2026 г., 11:40 UTC

Обсуждения рынка
Отчет

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29 янв. 2026 г., 06:05 UTC

Отчет

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29 янв. 2026 г., 06:04 UTC

Отчет

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29 янв. 2026 г., 06:03 UTC

Отчет

Roche Issues 2026 View

29 янв. 2026 г., 06:02 UTC

Отчет

Analysts Saw 2025 Core EPS at CHF19.70

29 янв. 2026 г., 06:02 UTC

Отчет

Roche: 2025 Core EPS CHF19.46

29 янв. 2026 г., 06:01 UTC

Отчет

Analysts Had Seen 2025 Sales At CHF61.47B

29 янв. 2026 г., 06:01 UTC

Отчет

Roche 2025 Sales CHF61.52B

28 янв. 2026 г., 11:22 UTC

Отчет

Roche's Prospects in Weight-Loss Field to be in Focus -- Earnings Preview

27 янв. 2026 г., 11:31 UTC

Обсуждения рынка

Roche's Weight-Loss Study Results Seem Promising -- Market Talk

27 янв. 2026 г., 11:24 UTC

Обсуждения рынка

Roche Might Struggle to Leave Mark in Crowded Obesity Market With CT-388 -- Market Talk

27 янв. 2026 г., 09:30 UTC

Обсуждения рынка

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

27 янв. 2026 г., 07:52 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Roche Obesity Study Data Look Encouraging -- Market Talk

16 янв. 2026 г., 17:03 UTC

Обсуждения рынка

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

12 янв. 2026 г., 14:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Pharma Sector Can Spend Big on M&A -- Market Talk

22 дек. 2025 г., 08:48 UTC

Обсуждения рынка

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

19 нояб. 2025 г., 12:47 UTC

Обсуждения рынка

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

10 нояб. 2025 г., 12:16 UTC

Обсуждения рынка
Отчет

Roche Results for MS-Treatment Candidate Look Encouraging -- Market Talk

23 окт. 2025 г., 09:19 UTC

Обсуждения рынка
Отчет

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23 окт. 2025 г., 09:11 UTC

Обсуждения рынка
Отчет

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23 окт. 2025 г., 05:09 UTC

Отчет

Roche 3Q Sales Up 6% At CER

23 окт. 2025 г., 05:07 UTC

Отчет

Roche 3Q Sales CHF14.92B

23 окт. 2025 г., 05:07 UTC

Отчет

Analysts Had Seen 3Q Sales At CHF15.17B

23 окт. 2025 г., 05:07 UTC

Отчет

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

23 окт. 2025 г., 05:05 UTC

Отчет

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

Сравнение c конкурентами

Изменение цены

Roche Holding AG Прогноз

Консенсус по рейтингу

By TipRanks

0 ratings

0

Покупка

0

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat